LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $98.00 Average PT from Analysts

Key Points

• LeMaitre Vascular has received a consensus rating of “Moderate Buy” from six brokerages, with an average 12-month price target of $98.00.
• Insider transactions included significant sales by directors, with John A. Roush and David B. Roberts selling a combined total of 17,376 shares, reflecting a notable decrease in their ownership stakes.
• The company reported $0.60 earnings per share for the last quarter, exceeding estimates and showing a 15.0% increase in year-over-year revenue.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has received a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $98.00.

A number of research analysts recently commented on LMAT shares. Cantor Fitzgerald increased their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a report on Wednesday, August 6th.

Insider Activity

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company's stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. This trade represents a 5.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 202,082 shares of company stock worth $18,249,066 in the last ninety days. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors have recently modified their holdings of the stock. First Trust Advisors LP raised its stake in LeMaitre Vascular by 52.7% in the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier's stock worth $50,829,000 after buying an additional 211,280 shares in the last quarter. Annex Advisory Services LLC grew its holdings in LeMaitre Vascular by 535.2% in the second quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier's stock worth $18,243,000 after purchasing an additional 185,085 shares during the last quarter. Raymond James Financial Inc. purchased a new position in LeMaitre Vascular in the fourth quarter worth $14,900,000. Millennium Management LLC grew its holdings in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock worth $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Finally, Grandeur Peak Global Advisors LLC purchased a new position in LeMaitre Vascular in the second quarter worth $6,275,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock traded up $0.10 during trading on Friday, reaching $95.91. 270,698 shares of the stock traded hands, compared to its average volume of 171,617. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of 46.56, a P/E/G ratio of 2.47 and a beta of 0.79. The business has a fifty day simple moving average of $84.56 and a two-hundred day simple moving average of $86.34. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same quarter last year, the firm earned $0.52 EPS. The firm's revenue for the quarter was up 15.0% compared to the same quarter last year. Sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 annualized dividend and a yield of 0.8%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 38.83%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.